Stage II BRCA1 Invasive Ductal Carcinoma: Stephanie's Patient Story

Patient Info: Stephanie Hargis, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

Stephanie had Stage II triple-negative breast cancer with BRCA1 mutation, then a local recurrence in April 2023 without distant spread; after surgery, chemotherapy, Keytruda, radiation, and Lynparza, she remained in ongoing post-recurrence treatment.

BreastCancer.org (ES)Read more →

BRCA1 Breast Cancer: Alina's Survivor Story

Patient Info: Alina Schiller, Female, Under 40

Biomarkers: BRCA1 mutation

By August 2023, Alina was cancer-free after fertility preservation, chemotherapy, bilateral mastectomy with lymph node removal, radiation therapy, rehabilitation, and psycho-oncology support for early-stage BRCA1-associated breast cancer.

Krankheitserfahrungen.deRead more →

BRCA1 Breast Cancer: Julia's Patient Story

Patient Info: Julia Bring, Female, Under 40

Biomarkers: BRCA1 mutation

Julia had recurrent disease in the axilla with metastases mentioned after initial treatment, then underwent additional surgery, chemotherapy, and radiation while coping with lymphoedema, infertility, weight gain, and retraining needs.

Krankheitserfahrungen.deRead more →

BRCA1 Breast Cancer: Jasmin's Patient Story

Patient Info: Jasmin Nussing, Female, Under 40

Biomarkers: BRCA1 mutation

Jasmin completed major breast cancer treatment while continuing technical school, had BRCA1-related long-term risk management ahead, and required ongoing heart monitoring related to antibody/immunotherapy.

Krankheitserfahrungen.deRead more →

Stage II Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy, Female, Under 40 | Stage II

Biomarkers: Germline BRCA1 mutation; triple-negative breast cancer

Surgical pathology was all clear on June 17 after a strong chemotherapy response. Lucy described herself as cancer-free and continued oncology reviews every 3–4 months while planning delayed reconstruction.

The Patient StoryRead more →

Stage III Triple-Negative Breast Cancer: Stephanie's Survivor Story

Patient Info: Stephanie, Female | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of June 2026, Stephanie described being a 10-year survivor after Stage III BRCA1-positive triple-negative breast cancer, with remission shown after chemotherapy and no recurrence described.

The Patient StoryRead more →

Stage II BRCA1 Breast Cancer: Joy's Survivor Story

Patient Info: Joy R., Female | Stage II

Biomarkers: BRCA1 mutation

As of June 2026, Joy had no evidence of disease after chemotherapy, double mastectomy, and hysterectomy for Stage II breast cancer with a BRCA1 mutation, and had moved from 3-month to 6-month oncology monitoring.

The Patient StoryRead more →

Stage ypT1aN0 triple-negative breast cancer with familial BRCA1 and OBSCN deletions

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative breast cancer; HER2 1+/negative; Ki-67 20%+. Familial testing showed BRCA1 and OBSCN deletions.

She underwent modified radical mastectomy with sentinel lymph node dissection and continued postoperative follow-up, with the main clinical emphasis on familial BRCA1/OBSCN genetic susceptibility.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Marina's Survivor Story

Patient Info: Marina, Female, Under 40

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Triple-negative breast cancer survivor with a BRCA1 mutation who completed treatment after an initial diagnosis and a second diagnosis at the 5-year mark; no formal stage or metastatic disease was stated in the available source text.

The Patient StoryRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Rancik, Female, Under 40 | Stage II

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Jennifer entered remission in October 2017 after Stage II triple-negative breast cancer treatment and, as of October 2025, reported doing great and being off medications except occasional Zometa.

City of HopeRead more →

Synchronous triple-negative breast cancer and rectal adenocarcinoma complicated by hepatitis B reactivation

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer with pathogenic BRCA1 mutation; hepatitis B reactivation occurred during treatment.

At 3-year follow-up, she remained healthy and disease-free after treatment for synchronous triple-negative breast cancer and mid-rectal adenocarcinoma, with hepatitis B reactivation controlled on entecavir.

PubMed CentralRead more →

Stage III Triple-Negative Breast Cancer: Paula's Survivor Story

Patient Info: Paula Jones, Female, 40s | Stage III

Biomarkers: Triple-negative breast cancer; BRCA1 mutation

As of July 2025, Paula had remained cancer-free for more than 15 years after Stage IIIC triple-negative breast cancer treatment and was training to become a mammography technologist.

MD AndersonRead more →

BRCA1 Breast Cancer: Kathy's Survivor Story

Patient Info: Kathy Baker, Female

Biomarkers: BRCA1 mutation

As of June 2025, Kathy Baker was a breast and ovarian cancer survivor using her experience with BRCA1 testing to advocate for genetic testing access and cascade testing through My Faulty Gene.

Metastatic male breast cancer: complete metabolic response after restarting anastrozole, leuprolide, abemaciclib, zoledronic acid, and radiation

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER >95%; PR >95%; HER2/neu-negative; Ki-67 30%; PIK3CA exon 21 pathogenic variant; BRCA1 not mutated; BRCA2 not mutated

Metastatic Site: bone (vertebral bodies T2-T6, L1, and L5)

As of May 2025, after restarting endocrine and targeted therapy and receiving palliative radiation, the last two PET scans showed complete metabolic response without disease progression, and brain MRI showed no metastasis.

PubMed CentralRead more →

Breast Cancer in a Woman Carrying Both BRCA1 and BRCA2 Mutations

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER-positive, PR-positive, HER2-negative, BRCA1 pathogenic variant, BRCA2 pathogenic variant

Remained free of recurrence 17 months after treatment.

PubMed CentralRead more →

Facing Triple-Negative Breast Cancer: Chance’s Story

Patient Info: Chance, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of February 2025, Chance described follow-up after Stage II BRCA1-associated triple-negative breast cancer and stated that she did not currently have cancer, while continuing close surveillance.

The Patient StoryRead more →

Triple-negative breast cancer: partial response to TAC chemotherapy

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Triple-negative breast cancer with EGFR positivity and high Ki-67; BRCA1 staining was positive by IHC.

After 1 cycle of TAC chemotherapy, the large ulcerated breast tumor shrank enough for surgery. Radical mastectomy with adjacent flap transfer achieved clear margins and no nodal metastatic cancer; she was recovering at home while awaiting planned postoperative AC-T chemotherapy.

PubMed CentralRead more →

Triple-Negative Pleomorphic Lobular Breast Cancer in a BRCA1 Carrier

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative, BRCA1 pathogenic mutation

Surgery after neoadjuvant treatment showed a complete pathologic response with no cancer in the 2 sampled sentinel lymph nodes.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer: Chance's Survivor Story

Patient Info: Chance Osborne, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of March 2024, Chance Osborne was a young Stage II TNBC survivor with a BRCA1 mutation, sharing her experience with chemotherapy, double mastectomy recovery, and advocacy.

Stage II Triple-Negative Breast Cancer: Chantal's Survivor Story

Patient Info: Chantal, Female, Under 40 | Stage II

Biomarkers: Triple-negative breast cancer; BRCA1 mutation

As of December 2023, Chantal reported that she did not currently have cancer, was followed by medical oncology every 3-4 months, and used Signatera testing because tumor markers were not reliable for her.

The Patient StoryRead more →

Stage IV Triple-Negative Breast Cancer: April's Patient Story

Patient Info: April Donaldson, Female, 40s | Stage IV

Biomarkers: Triple-negative breast cancer; BRCA1 positive

Metastatic Site: Lungs

As of September 2023, April was living with Stage IV metastatic triple-negative breast cancer in the lungs; scans were stable in February but showed growth again in July, and PARP inhibitor therapy was being planned.

The Patient StoryRead more →

BRCA1 Breast Cancer: Carol's Survivor Story

Patient Info: Carol Arnhart

Biomarkers: BRCA1 mutation

She had a complete pathologic response to breast chemotherapy and later reported no evidence of breast cancer.

MD AndersonRead more →

Stage IIB Breast Cancer Treatment Followed by BRCA1 Testing

Patient Info: Anonymized, Female | Stage II

Biomarkers: BRCA1 pathogenic variant

She completed 10 years of endocrine therapy without evidence of breast-cancer recurrence.

PubMed CentralRead more →